Drug intelligence / Profile preview

EVG-332

Development stage: Preclinical
Lead developer: Evergreen Theragnostics
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

EVG-332 is a radiotracer in preclinical development for the treatment of pancreatic ductal adenocarcinoma (PDAC). It targets a cell surface molecule associated with PDAC, aiming to improve outcomes for patients with this aggressive cancer. The drug is being developed by Evergreen Theragnostics and is classified as a therapeutic radiopharmaceutical. Pancreatic ductal adenocarcinoma has a poor prognosis, especially in cases with distant metastatic disease[1][2].

Beyond the preview

Go deeper on EVG-332.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EVG-332.

Explore the full profile